BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Saladax Biomedical Laboratories to Offer the Full Portfolio of MyCare™ Therapeutic Dose Management Assays in the United States


2/11/2013 9:42:34 AM

BETHLEHEM, Pa., Feb. 11, 2013 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine, announced today that the My5-FU Assay will be part of the Saladax Biomedical Laboratories MyCare service offering when the CLIA laboratory located in Bethlehem, PA commences operations later this year.

My5-FU is a simple blood test that provides oncologists with objective information to guide optimized dosing of 5-fluorouracil (5-FU), controlling toxic side effects and improving treatment efficacy for cancer patients. The test has been offered in the United States by Myriad Genetics, Inc. under the trade name OnDoseĀ®, but rights to this assay will revert to Saladax when the Saladax Biomedical CLIA lab becomes operational in June 2013.

"We're extremely pleased to bring our entire line of MyCare oncology therapeutic dose management assays under one roof," said Kevin Harter, CEO & President of Saladax. "With the creation of the Saladax Biomedical Laboratories, cancer patients in the US can be better served with a single source for all oncology dose management testing services."

"The CLIA laboratory expands the business model beyond the supply of diagnostic reagent kits in other markets of the world to include a clinical testing service for the US market. Saladax can provide assistance to cancer patients through channels best suited in specific markets," added Mark D. Myslinski, Senior VP and Chief Commercial Officer.

Saladax Biomedical Laboratories will initially be offering testing services for MyPaclitaxel and MyDocetaxel, as well as My5-FU, and the menu will be further expanded with an additional 10 oncology dose management assays as their development is completed. The MyCare technology platform offers automated, rapid, robust and cost-effective blood tests for patient-specific chemotherapy dose optimization. These tests enable a physician to determine the optimal treatment effectiveness/toxicity balance for each unique patient.

OnDose will continue to be promoted and sold by Myriad through June, when the Saladax Biomedical Laboratories becomes operational and the customer base is transitioned to Saladax.

About Saladax Biomedical, Inc.

Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCare assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development. Three MyCare assays, My5-FU, MyPaclitaxel and MyDocetaxel, are currently offered to the oncology community in markets around the world and will be available from Saladax Biomedical Laboratories mid-year 2013.

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories. This technology also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified. CLIA # 39D2052285.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Sr. VP & Chief Operating Officer
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Andrew Mielach/Claire Sojda
amielach@tiberend.com; (212) 375-2694
csojda@tiberend.com; (212) 375-2686

SOURCE Saladax Biomedical, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES